Dr. Nancy J Bunin, MD
Claim this profileChildren's Hospital of Philadelphia
Studies Primary Immunodeficiency
Studies Constitutional Mismatch Repair Deficiency Syndrome
17 reported clinical trials
21 drugs studied
Area of expertise
1Primary Immunodeficiency
IgG to EBV positive
T-cell response to BZLF-1 positive
T-cell response to NA-1 positive
2Constitutional Mismatch Repair Deficiency Syndrome
IgG to EBV positive
T-cell response to BZLF-1 positive
T-cell response to NA-1 positive
Affiliated Hospitals
Clinical Trials Nancy J Bunin, MD is currently running
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Nancy J Bunin, MD
Clinical Trial Related7 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Nancy J Bunin, MD has experience with
- Busulfan
- Alpha/Beta T And CD19+ Depleted Peripheral Stem Cells
- Cell Depletion Using CliniMACS Device
- TCRαβ + T Cell And CD45RA Depleted Peripheral Stem Cell Addback
- Transplant Of Stem Cells With CD3+/CD19+ Depletion (CliniMACs)
- Allogeneic Stem Cell Transplant
Breakdown of trials Nancy J Bunin, MD has run
Primary Immunodeficiency
Constitutional Mismatch Repair Deficiency Syndrome
Leukemia
Immunodeficiency
Infections and Infestations
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nancy J Bunin, MD specialize in?
Nancy J Bunin, MD focuses on Primary Immunodeficiency and Constitutional Mismatch Repair Deficiency Syndrome. In particular, much of their work with Primary Immunodeficiency has involved IgG to EBV positive patients, or patients who are T-cell response to BZLF-1 positive.
Is Nancy J Bunin, MD currently recruiting for clinical trials?
Yes, Nancy J Bunin, MD is currently recruiting for 13 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Nancy J Bunin, MD has studied deeply?
Yes, Nancy J Bunin, MD has studied treatments such as Busulfan, Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells, Cell Depletion using CliniMACS device.
What is the best way to schedule an appointment with Nancy J Bunin, MD?
Apply for one of the trials that Nancy J Bunin, MD is conducting.
What is the office address of Nancy J Bunin, MD?
The office of Nancy J Bunin, MD is located at: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the Children's Hospital of Philadelphia.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.